New Drug Lowers Heart Risks by Curbing Inflammation

New Drug Lowers Heart Risks by Curbing Inflammation

New Drug Lowers Heart Risks by Curbing Inflammation

$NVS

For the 1st time, a drug has helped prevent heart attacks by curbing inflammation, a new and very different approach than lowering cholesterol.

People on the drug also had surprisingly lower cancer death rates, especially from lung cancer. An anti-tumor effect is an exciting possibility.

Doctors say the results on the drug, canakinumab (can-uh-KIN-yoo-mab), open a new frontier. Many heart attacks occur in people whose cholesterol is normal and whose main risk is chronic inflammation that can lead to clogged arteries.

“We suddenly know we can address the inflammation itself, the same way we learned almost 25 years ago that we could address cholesterol. It’s very exciting,” said the study’s leader, Dr. Paul Ridker of Brigham and Women’s Hospital in Boston.

Sunday,the results were published Sunday by the New England Journal of Medicine and Lancet, and presented at the European Society of Cardiology conference in Barcelona, Spain.

The drug’s maker, Novartis (NYSE:NVS) sponsored the study Dr. Ridker consults for the company.

Statins such as Lipitor lower LDL or bad cholesterol and have been the cornerstone of preventing heart attacks along with not smoking, blood pressure control and a healthy lifestyle.

Yet, 25% of people who suffer a heart attack will have another one within 5 years, and inflammation is a the Key reason in 50% of those cases.

Inflammation happens after a joint is injured and swells, but similar chemical responses can occur over time throughout the body with unhealthy habits. That chronic, unseen inflammation can damage arteries and set the stage for clots.

20 years ago, Dr. Ridker helped clarify its role and patented a cheap blood test for a sign of inflammation called high-sensitivity C-reactive protein, or CRP.

Canakinumab lowers CRP and is sold now under the brand name Ilaris for some rare inherited diseases.

The study tested it in 10,000 heart attack survivors with low cholesterol but high CRP. They got the usual heart medicines including statins and were given one of three different doses of canakinumab or a placebo as a shot every 3 months.

Those on the medium dose had a 15% lower chance of another heart attack, a stroke or a heart-related death over the next 4 years compared to people given dummy shots.

About 33 people would have to be treated for 5 years to prevent 1 of these problems, a ratio that outside experts called very good.

The highest dose also lowered risk but not by enough to say the drug was the reason. The lowest dose had no effect.

Canakinumab’s benefit was comparable to Repatha, a powerful new type of cholesterol-lowering drug called a PCSK9 inhibitor. It came out 2 years ago and has had soft sales, partly because many doctors hoped it would help more and due to its price at $14,000 a year.

It’s hard to get big reductions in risk by adding a new drug like canakinumab if people already are taking optimal medicines, said Dr. Mark Creager, director of the Dartmouth-Hitchkock heart and vascular center and past president of the American Heart Association.

But even a small improvement makes a huge difference considering how common heart attacks are, he said. “That’s going to save a lot of people.”

The best part is having a new way to help patients, said the Cleveland Clinic’s heart chief, Dr. Steven Nissen, who has consulted for Novartis without fee.

“For the first time we have this new target — inflammation,” Dr. Nissen said. “It’s sort of the dawning of a new era. I really think it’s that big.”

Inflammation also affects how cancers grow and spread. The cancer death rate was only 50% as large among those getting canakinumab, and death rates for lung cancer were lower in people getting the top 2 doses.

Doctors do not think the drug prevents new cancers from developing, but that it might slow the growth of any tumors that had already started, based on other research.

The cancer results were unexpected and intriguing, but not consistent across all types of tumors, said Dr. Barnett Kramer, prevention chief at the National Cancer Institute.

He called the lower risk for lung cancer “a promising lead” for future research, but said it comes with concern about the drug’s side effects.

 

Novartis said it’s premature to discuss price for any use as a heart medicine. It costs as much as $200,000 now for rare diseases, and would have to prove cost-effective to justify its relatively modest benefits and risks for heart disease prevention, Dr. Robert Harrington, Chairman of the department of medicine at Stanford University, wrote in a commentary in the New England Journal.

The company said it would discuss the new results with regulators and pursue further studies on the lung cancer possibilities.

Drugs called NSAIDs, such as ibuprofen, fight inflammation and pain, can raise heart risks, which may seem confusing in light of this study. But they work in a different way, do not reduce CRP, and can affect blood clot formation.

Symbol Last Trade Date Change Open High Low Volume
NYSE:NVS 83.53 25 August 2017 -0.05 83.64 84.094 83.525 1,485,800
HeffX-LTN Analysis for NVS: Overall Short Intermediate Long
Neutral (-0.03) Bearish (-0.39) Neutral (-0.10) Bullish (0.39)

Eat healthy, Be healthy, Drink pure water, Live lively,

Have a terrific week.

The following two tabs change content below.

Paul Ebeling

Paul A. Ebeling, polymath, excels in diverse fields of knowledge. Pattern Recognition Analyst in Equities, Commodities and Foreign Exchange and author of “The Red Roadmaster’s Technical Report” on the US Major Market Indices™, a highly regarded, weekly financial market letter, he is also a philosopher, issuing insights on a wide range of subjects to a following of over 250,000 cohorts. An international audience of opinion makers, business leaders, and global organizations recognizes Ebeling as an expert.

You must be logged in to post comments :  
CONNECT WITH